论文部分内容阅读
目的:探讨大黄虫丸抗血小板活化的作用。方法:用大黄虫丸含药血浆孵育血小板,然后用ADP诱导活化,血小板膜糖蛋白GPⅡb/Ⅲa复合物纤维蛋白原受体(PAC-1)单克隆抗体标记,流式细胞术分析血小板的活化。同时,冠心病及脑梗死患者服用大黄虫丸,治疗1疗程(30d)后,取患者血小板,采用流式细胞术分析患者血小板的活化。结果:大黄虫丸药物体外血浆组血小板活化率为20.82%,阿司匹林组血小板活化率为51.71%,大黄虫丸组血小板活化明显低于阿司匹林组(P<0.01)。在临床治疗冠心病试验中,服用大黄虫丸患者血小板活化率为14.78%,明显低于服用阿司匹林患者血小板活化率67.74%(P<0.01);对于脑梗塞患者,服用大黄虫丸患者血小板活化率为5.65%,低于阿司匹林患者组77.91%(P<0.01)。结论:大黄虫丸能较好的抑制血小板活化,可能是理想的抗动脉血栓形成药物。
Objective: To investigate the anti-platelet activation effect of Dahuangchong Pills. METHODS: Platelets were incubated with Dahuang Pill-containing plasma and activated with ADP. The platelet membrane glycoprotein GPIIb/IIIa complex fibrinogen receptor (PAC-1) monoclonal antibody was used to identify platelet activation by flow cytometry. . At the same time, patients with coronary heart disease and cerebral infarction were treated with Dahuangchong Pill. After one course of treatment (30 days), the patient’s platelets were taken and platelet activation was analyzed by flow cytometry. Results: The platelet activation rate was 20.82% in the in vitro plasma group and 51.71% in the aspirin group. The platelet activation in the Dahuang Pill Pill group was significantly lower than that in the aspirin group (P<0.01). In the clinical trial of coronary heart disease, the platelet activation rate of patients taking Dahuangchong Pills was 14.78%, which was significantly lower than the platelet activation rate of patients taking aspirin 67.74% (P<0.01); for patients with cerebral infarction, the platelet activation rate of patients taking Dahuangchong Pills It was 5.65%, 77.91% lower than the aspirin patient group (P<0.01). Conclusion: Dahuangchong Pill can inhibit platelet activation better. It may be an ideal anti-arterial thrombosis drug.